Our study aimed to evaluate the exposure–response relationship between incretin-based medications and the risk of major adverse cardiovascular events (MACE) using cardiovascular outcome trials (CVOTs). Eleven CVOTs with incretin-based medications were included. The median follow-up time, percentage of time exposure, and hazard ratio (HR) of MACE were obtained from each CVOT. The pharmacokinetic parameters of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitor (DPP-4) were obtained from published studies. Regression analysis was performed to assess the relationship between drug exposure and MACE HR. Cutoff values were determined from the ROC curves. The linear regression results indicated that log Cmax, log AUC0–24h, and log AUCCVOT are negatively correlated with MACE HR (R² = 0.8494, R² = 0.8728, and R² = 0.8372, respectively; all p < 0.0001). The relationship between drug exposure (log Cmax, log AUC0–24h, and log AUCCVOT) and MACE HR strongly corresponded with the log (inhibitor) vs. response curve (R² = 0.8383, R² = 0.8430, and R² = 0.8229, respectively). The cutoff values in the ROC curves for log Cmax, log AUC0–24h, and log AUCCVOT, were 2.556, 3.868, and 6.947, respectively (all p = 0.007). A Fisher’s exact test revealed that these cutoff values were significantly related to cardiovascular benefits (all p < 0.05). Our study revealed a linear exposure–response relationship between drug exposure and MACE HR. We conclude that the cardiovascular benefits of incretin-based therapies may occur with higher doses of GLP-1 RAs and with increased exposure.

Keywords: type 2 diabetes mellitus, cardiovascular outcome trials, glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor, incretin

INTRODUCTION

Type 2 diabetes (T2DM) is frequently accompanied by various cardiovascular complications. Further, cardiovascular complications are the leading cause of disability and death in patients with T2DM (1). Numerous in vitro studies and animal studies have investigated the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists (GLP-1 RAs) on the cardiovascular
system (2, 3). Considering the results of cardiovascular outcome trials (CVOTs) with incretin-based medications, significant heterogeneity in cardiovascular effects could be found between DPP-4 inhibitors and GLP-1 RAs. While the results obtained with DPP-4 inhibitors (alogliptin, saxagliptin, sitagliptin, and linagliptin) demonstrated cardiovascular safety (4–7), the majority of GLP-1 RAs (including liraglutide, albiglutide, dulaglutide, and subcutaneous semaglutide) significantly decreased the risk of major adverse cardiovascular events (MACE) (8–11). Furthermore, the meta-analysis results suggested that the GLP-1RA class could reduce the risk of MACE, cardiovascular mortality, and all-cause mortality (12). However, the results of the ELIXA study with lixisenatide (cardiovascular safety) (13), the PIONEER 6 study with oral semaglutide (cardiovascular safety) (14), and the EXSCEL study with extended exenatide (a trend toward reduction in MACE) (15), cast doubt on the existence of a class effect for GLP-1 RAs.

Although our overall understanding of the cardiovascular benefits of GLP-1RAs has evolved over time, head-to-head comparisons between different incretin-based drugs in the completed CVOTs have been lacking. Hence, differences in baseline characteristics/trial execution may account for the divergent MACE results. However, evidence from several studies suggest associations between cardiovascular risk reduction and HbA1c reduction (16), non-glycemic effects (17), or time of exposure to GLP-1 RAs (18). In the present study, we evaluated the exposure–response relationship of incretin-based medications by determining the effects of drug exposure on MACE risk in cardiovascular outcome trials.

RESEARCH DESIGN AND METHODS

In total, 11 CVOTs comparing add-on therapy using a DPP-4 inhibitor or GLP-1RA with a placebo were included. HbA1c reduction, weight loss, median follow-up time, percentage of time exposure to the trial drug, and hazard ratio (HR) of 3-point MACE in each individual CVOT were obtained from the records. Although the plasma concentration of GLP-1 RAs or GLP-1 was not measured in the CVOTs, the clinical pharmacokinetic and pharmacodynamic properties of these trial drugs have previously been established and published. The maximum observed plasma concentration of GLP-1 RA or active GLP-1 (C_{max}), the mean area under the curve (AUC_{0–24h}) with multiple doses, and the total AUC in CVOT (AUC_{CVOT}) were used to assess drug exposure (Table 1). AUC_{CVOT} was calculated by substituting the median follow-up time and percentage of time exposure to the trial drug using Eq. 1, as follows:

\[
\text{AUC}_{\text{CVOT}} = \text{AUC}_{0–24h} \times \text{Median follow – up time} \times \text{Percentage of time exposure to trial drug}
\]

Measurements of normalized cyclic adenosine monophosphate (cAMP) production, induced by GLP-1 RAs (19), was used to calibrate C_{max}, AUC_{0–24h}, and AUC_{CVOT}. Using the calibrated C_{max} calibrated AUC_{0–24h}, and calibrated AUC_{CVOT}, a sensitivity analysis was conducted to assess the exposure–response relationship.

STATISTICAL ANALYSES

The values of C_{max}, AUC_{0–24h}, and AUC_{CVOT} were obtained as continuous variables and analyzed after natural logarithmic transformation. Linear regression analysis was used to assess the relationship between drug exposure (log C_{max}, log AUC_{0–24h}, or log AUC_{CVOT}) and MACE HR, HbA1c reduction, and weight loss. Nonlinear regression analysis was used to examine the exposure–response relationship by fitting a log (inhibitor) vs. response curve. Continuous variables were evaluated using receiver operating characteristic (ROC) curves. Cutoff values were determined following an assessment of the ROC curves. Fisher’s exact tests were used to compare categorical variables. A p value < 0.05 was used to determine statistical significance. All analyses were performed using GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA).

RESULTS

Drug Exposure

C_{max}, AUC_{0–24h}, and AUC_{CVOT} of GLP-1 RAs and native GLP-1 are reported in Table 2. According to the pharmacodynamic studies of alogliptin, saxagliptin, sitagliptin, and linagliptin, the DPP4 inhibitors significantly increased native GLP-1 levels in patients with T2DM (compared with placebo), yielding an average level of ≤ 19.0 pmol/L (Table 2 and Figure S1) (20–23).

Pharmacokinetic studies of GLP-1 RAs revealed that the plasma concentrations of GLP-1 RAs in T2DM patients varied significantly. The peak plasma concentration of lixisenatide was 187.2 pg/mL (38.5 pmol/L) after multiple daily injections (24), while the steady-state plasma concentration of once-weekly exenatide reached 300 pg/mL (71.4 pmol/L) after multiple

| Parameters       | Description                                                                 |
|------------------|-----------------------------------------------------------------------------|
| C_{max}          | The maximum observed plasma concentration of GLP-1 RA or active GLP-1 with multiple doses. C_{max} represents exposure concentration of drug. |
| AUC_{0–24h}      | The mean drug exposure is expressed as the mean area under the curve from 0–24 hours. AUC_{0–24h} represents mean exposure concentration and time of drug. |
| AUC_{CVOT}       | Total drug exposure is expressed as the area under the curve during the median follow-up period of the individual CVOT. AUC_{CVOT} represents total exposure concentration and time of drug. |
TABLE 2 | Exposure–response related parameters.

| Trial                  | MACE HR | Mean follow up (years) | Percentage of time exposure to trial drug | Cmax (pmol/L) | AUC0–24h (pmol·h/L) | AUCCVOT (pmol·h/L) |
|-----------------------|---------|------------------------|------------------------------------------|---------------|---------------------|-------------------|
| EXAMINE (Alogliptin)  | 0.96    | 1.5                    | 0.97                                      | 14.2<sup>a</sup> | 132                 | 70155             |
| SAVOR-TIMI (Saxagliptin) (SUSTAIN-6 trial, HR, 0.74) | 1.00 | 2.1                    | 1.00                                      | 4.8<sup>a</sup> | 72<sup>d</sup> | 55188†           |
| TECOS (Sitagliptin)   | 0.98    | 3.0                    | 1.00                                      | 19.0<sup>a</sup> | 191                 | 208926            |
| CARMELINA (Linagliptin) | 1.02  | 2.2                    | 0.86                                      | 11.8<sup>a</sup> | 136                 | 93643             |
| ELIKA (Lixisenatide)  | 1.02    | 2.1                    | 0.88                                      | 38.5<sup>a</sup> | 175                 | 117704            |
| EXSCEL (Exenatide OW) | 0.91    | 3.2                    | 0.76                                      | 71.4<sup>ab</sup> | 1717                | 1523791           |
| LEADER (Liraglutide)  | 0.87    | 3.8                    | 0.84                                      | 22000.0<sup>ab</sup> | 524000              | 610501920         |
| HARMONY (Albiglutide) | 0.78    | 1.6                    | 0.87                                      | 29178.0<sup>ab</sup> | 622309              | 316182858         |
| SUSTAIN-6 (Semaglutide 0.5 mg) | 0.71  | 2.1                    | 0.87                                      | 30000.0<sup>ab</sup> | 719143              | 479564039         |
| SUSTAIN-6 (Semaglutide 0 mg) | 0.77 | 2.1                    | 0.87                                      | 15800.0<sup>ab</sup> | 380429              | 253690714         |
| REWIND (Dulaglutide)  | 0.88    | 5.4                    | 0.82                                      | 1810.0<sup>ab</sup> | 31746               | 51308520          |
| PIONEER 6 (Oral semaglutide) | 0.79 | 1.3                    | 1.00                                      | 14600.0<sup>ab</sup> | 283700              | 137722165         |

*a once daily.
*b once weekly.
*c oral administration.
† the raw data were obtained from the visual graph of the published paper.
| Subcutaneous injection. |

Table 2 shows the results of our statistical analysis of the primary outcomes in the CVOTs, several of the add-on therapies demonstrated cardiovascular noninferiority when compared with placebo. These included alogliptin (EXAMINE trial, HR, 0.96; p < 0.001 for noninferiority and p = 0.32 for superiority) (4), saxagliptin (SAVOR-TIMI 53 trial, HR, 1.00; p < 0.001 for noninferiority and p = 0.99 for superiority) (5), sitagliptin (TECOS trial, HR, 0.98; p < 0.001 for noninferiority and p = 0.65 for superiority) (6), linagliptin (CARMELINA trial, HR, 1.02; p < 0.001 for noninferiority and p = 0.74 for superiority) (7), lixisenatide (ELIKA trial, HR, 1.02; p < 0.001 for noninferiority and p = 0.81 for superiority) (13), once-weekly exenatide (EXSCEL trial, HR, 0.91; p < 0.001 for noninferiority and p = 0.06 for superiority) (15), and oral semaglutide (PIONEER 6 trial, HR, 0.79; p < 0.001 for noninferiority and p = 0.17 for superiority) (14).

Conversely, liraglutide (LEADER trial, HR, 0.87; p < 0.001 for noninferiority and p = 0.01 for superiority) (8), albiglutide (HARMONY trial, HR, 0.78; p < 0.001 for noninferiority and p = 0.0006 for superiority) (9), dulaglutide (REWIND trial, HR, 0.88; p = 0.026 for superiority) (10), and subcutaneous semaglutide (SUSTAIN-6 trial, HR, 0.74; p < 0.0001 for noninferiority and p = 0.02 for superiority) (11) all demonstrated cardiovascular superiority over placebo (Table 2).

**Exposure–Response Relationship**

The linear regression results demonstrate that log Cmax, log AUC0–24h, and log AUCCVOT negatively correlate with MACE HR (R<sup>2</sup> = 0.8494, R<sup>2</sup> = 0.8728, and R<sup>2</sup> = 0.8372, respectively; p < 0.0001) (Figures 1A–C). The relationship between drug exposure (log Cmax, log AUC0–24h, or log AUCCVOT) and MACE HR showed a good correspondence with the fitted curve (R<sup>2</sup> = 0.8383; R<sup>2</sup> = 0.8430; R<sup>2</sup> = 0.8229, respectively; Figures 1D–F). The ROC curve was used to evaluate drug exposure and define cutoff values (Figure 2). For the log Cmax, log AUC0–24h, and Log AUCCVOT ROC curves, the cutoff values were 2.556, 3.868, and 6.947, respectively (all p < 0.007). Detailed results reporting areas under the curve, sensitivity, and specificity are shown in Table 3. These cutoff values were all significantly related to cardiovascular superiority (all p < 0.05, Fisher’s exact test).

A similar correlation existed in the secondary prevention cohorts with a history of CVD (p < 0.01; Figure S2), but not in the primary prevention cohorts without a history of CVD (Supplementary Figure S3). The relationships between drug exposure and HbA1c reduction (compared with placebo) and between drug exposure and weight loss (compared with placebo) were also examined (Supplementary Figures S4, S5). In both instances, statistically significant relationships were observed (p < 0.01). A sensitivity analysis was also performed on calibrated Cmax, Calibrated AUC0–24h, and...
DISCUSSION

In healthy subjects, basal plasma levels of native GLP-1 are generally below 10 pmol/L, while postprandial levels of GLP-1 rise to 10–30 pmol/L (31–33). In comparison, prediabetes or T2DM subjects generally demonstrate lower basal GLP-1 levels, and/or a reduction in GLP-1 response to oral glucose load (33). DPP4 inhibitors reportedly raise the postprandial levels of native GLP-1 approximately 2–4 fold (20, 34). However, the concentrations of most GLP-1 RAs (except lixisenatide and once-weekly exenatide) are substantially higher than the reported physiological concentrations of GLP-1.

Our results indicate that the exposure concentrations of DPP4 inhibitor (lixisenatide) and once-weekly exenatide associated with cardiovascular safety are low, as the concentrations of these drugs were close to physiological levels (picomolar levels). In contrast, the exposure concentrations of other GLP-1 RAs (except oral semaglutide), which are associated with cardiovascular benefits, are higher (nanomolar levels). A strong relationship between the exposure concentration and MACE HR was demonstrated through regression analysis (p < 0.0001). Moreover, a good fit was obtained between the observed relationship and the theoretically constructed model. The exposure–response relationship of GLP-1 was also demonstrated in a cross-sectional study, and linear regression analysis showed that higher glucose-stimulated GLP-1 levels were associated with clinically relevant lower blood pressure (associated with beneficial effects on the cardiovascular system) (35). In addition, a strong relationship was demonstrated between the mean and total drug exposure and MACE HR.
Drug exposure is dependent on both concentration and time. When only concentration was considered, our ROC results suggest that \( \log C_{\text{max}} > 2.556 \) (i.e., \( C_{\text{max}} > 359.7 \) pmol/L) could be a predictor for cardiovascular benefits. However, when both concentration and time were considered, our results indicate that \( \log \text{AUC}_{0-24h} > 3.868 \) and \( \log \text{AUC}_{\text{CVOT}} > 6.947 \) could be predictors for cardiovascular superiority. These results suggest that the drug should be continuously used at a steady-state \( C_{\text{max}} \) of 307.5 pmol/L per day for 3.29 years consecutively (the value was obtained by dividing \( \text{AUC}_{\text{CVOT}} \) by \( \text{AUC}_{0-24h} \)). Native GLP-1 levels when using DPP4 inhibitors and GLP-1 RA levels (lixisenatide and once-weekly exenatide) were both less than the predicted \( C_{\text{max}} \) values. Hence, these regimens show cardiovascular safety only. For PIONEER 6, the median exposure time was only 15.9 months. We predict that better results may be obtained by extending the exposure time with oral semaglutide.

The extent to which exendin-4-based agonists differ in cardiovascular effects from GLP-1-based agonists has been extensively debated. Although CVOTs do not provide evidence of any cardiovascular benefits of using exendin-4-based agonists, there is no evidence to suggest that exendin-4-based agonists attenuate activation of GLP-1 receptor signaling (2). The present study demonstrates significant associations between GLP-1 RA drug exposure and HbA1c reduction and between GLP-1 RA drug exposure and weight loss. HbA1c reduction and weight loss may both play important roles in mediating MACE benefits (16, 36). Compared with other GLP-1 RAs, the therapeutic benefits (HbA1c reduction, weight loss, and cardiovascular benefits) of using recommended and approved doses of lixisenatide or once-weekly exenatide, which reflect a tradeoff between the adverse effects and the therapeutic benefits (HbA1c reduction and weight loss) observed in phase 2–3 studies, are significantly reduced (37). Suboptimal GLP-1 RA drug exposure with exendin-4-based agonists may be a critical cause of their lack of cardiovascular benefits (similar time exposure, but lower dose exposure).

The importance of supraphysiological doses of GLP-1 was originally proposed by J.J. Holst (38). Holst considered moderately elevated GLP-1 concentrations to have a significant effect on pancreatic islets, higher concentrations to slow gastric emptying and reduce food intake, and much higher concentrations to lead to side effects (nausea, diarrhea, and vomiting) (38). Our study provides evidence to support the notion that higher GLP-1 RA drug exposure is associated with additional cardiovascular benefit.

This study has several limitations. The parameters for drug exposure were obtained from different studies and may be biased. Although the parameters for drug exposure were calibrated using normalized cAMP, a degree of bias may be inevitable. In addition, our study is based on trial level analyses using the published literature, and not on patient level analyses. Thus, some inferences based on these results may ultimately prove to be misleading.

In conclusion, our study demonstrates a good exposure–response relationship between drug exposure and MACE HR. Our results suggest that the cardiovascular benefits of incretin-based therapies may occur with higher exposure to GLP-1 RAs.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

**AUTHOR CONTRIBUTIONS**

QP, MY, contributed to data collection and analysis. LG contributed to the study design and interpretation. All authors approved the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by the China International Medical Foundation (grant Z-2017-26-1902).

**ACKNOWLEDGMENTS**

The authors acknowledge Dr. Yale Duan for his help in statistical analysis and medical writing.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.893971/full#supplementary-material

---

**TABLE 3 | ROC Curves of all continuous variables.**

| Variable     | Cutoff | P Value | Areas under the curve | Sensitivity | Specificity |
|--------------|--------|---------|-----------------------|-------------|-------------|
| \( \log C_{\text{max}} \) | 2.556  | 0.007   | 0.971                 | 100.0       | 85.7        |
| \( \log \text{AUC}_{0-24h} \) | 3.868  | 0.007   | 0.971                 | 100.0       | 85.7        |
| \( \log \text{AUC}_{\text{CVOT}} \) | 6.947  | 0.007   | 0.971                 | 100.0       | 85.7        |
REFERENCES

1. An Y, Zhang P, Wang I, Gong Q, Gregg EW, Yang W, et al. Cardiovascular and All-Cause Mortality Over a 23-Year Period Among Chinese With Newly Diagnosed Diabetes in the Da Qing IGT and Diabetes Study. Diabetes Care (2015) 38(7):1365–71. doi: 10.2337/dc14-2498

2. Drucker DJ. The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications. Diabetes (2018) 67(9):1710–9. doi: 10.2337/db18-0008

3. Bistola V, Lambamadi V, Dimitriadis G, Ioannidis I, Makrilakis K, Tentolouris N, et al. Possible Mechanisms of Direct Cardiovascular Impact of GLP-1 Agonists and DPP4 Inhibitors. Heart Fail Rev (2018) 23(3):577–88. doi: 10.1007/s10741-018-9674-3

4. White WB, Cannon CP, Heller SR, Nissen SE, Bengtsson RM, Bakris GL, et al. Alagliptin After Acute Coronary Syndrome in Patients With Type 2 Diabetes. N Engl J Med (2013) 369(4):1327–35. doi: 10.1056/NEJMo1305889

5. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. N Engl J Med (2013) 369(14):1317–26. doi: 10.1056/NEJMo1307684

6. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Patients With Type 2 Diabetes. N Engl J Med (2015) 373(3):323–42. doi: 10.1056/NEJMo1531352

7. Rosenson J, Perkovic V, Jansons OE, Cooper ME, Kahn SE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and Established Cardiovascular Risk: The Carmelina Randomized Clinical Trial. JAMA (2019) 321(1):69–79. doi: 10.1001/jama.2018.18269

8. Marso SP, Daniels GH, Braun-Frandsen K, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes. N Engl J Med (2016) 375(4):311–22. doi: 10.1056/NEJMo1603827

9. Hernandez AF, Green JB, Jainmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): A Double-Blind, Randomised Placebo-Controlled Trial. Lancet (2018) 392(10157):1519–29. doi: 10.1016/S0140-6736(18)32261-X

10. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial. Lancet (2019) 394(10193):121–30. doi: 10.1016/S0140-6736(19)31449-3

11. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Idoar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes. N Engl J Med (2016) 375(19):1834–44. doi: 10.1056/NEJMo1607141

12. Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al. Cardiovascular Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes: A Meta-Analysis. Lancet Diabetes Endocrinol (2018) 6(2):105–15. doi: 10.1016/S2215-8587(17)30142-6

13. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Orlistat in Patients With Type 2 Diabetes Mellitus: Analysis of Meal Tolerance Test Data. Drugs R D (2014) 14(4):301–8. doi: 10.2968/jour.1.2013-0072-6

14. Nakamura Y, Tsuchi M, Hasegawa H, Kimura K, Fujita K, Inoue M, et al. Anti-Inflammatory Effects of Linagliptin in Hemodialysis Patients With Diabetes. Hemodial Int Symp Home Hemodial (2014) 18(2):433–42. doi: 10.1111/hdi.12127

15. Barnett AH. Lisixanestat: Evidence for Its Potential Use in the Treatment of Type 2 Diabetes. Core Evid (2011) 6:67–79. doi: 10.2147/CEJ.S15525

16. Murphy CE. Review of the Safety and Efficacy of Exenatide Once Weekly for the Treatment of Type 2 Diabetes Mellitus. Ann Pharmacother (2012) 46(6):812–21. doi: 10.1345/aph.1Q222

17. Ingwall JS, Shi, Petri KC, Tandon N, Yoon KH, Chen L, Vora J, et al. Liraglutide Pharmacokinetics and Dose-Exposure Response in Asian Subjects With Type 2 Diabetes From China, India and South Korea. Diabetes Res Clin Pract (2015) 108(1):113–9. doi: 10.1016/j.diabres.2015.01.001

18. Seino Y, Nakajima H, Miyahara H, Kurita T, Bush MA, Yang F, et al. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Albiglutide, a Long-Acting GLP-1-Receptor Agonist, in Japanese Subjects With Type 2 Diabetes Mellitus.Curr Med Res Opin (2009) 25(12):3049–57. doi: 10.1185/03007990903792999

19. Carlsson Petri KC, Ingwerson SH, Flint A, Zacho J, Overgaard RV. Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis. Diabetes Ther (2018) 9(4):1333–47. doi: 10.1007/s13300-018-0458-5

20. Geiser JS, Heathman MA, Cui X, Martin J, Loghin C, Chien JY, et al. Clinical Pharmacokinetics of Dulaglutide in Patients With Type 2 Diabetes: Analyses of Data From Clinical Trials. Clin Pharmacokinet (2016) 55(5):625–34. doi: 10.1007/s40262-015-0338-3

21. Food and Drugs Administration. Drug RYBELSUS: Drug Details: Label Information (2019). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf (Accessed 1 Aug 2020).

22. Acidich V, Omar B, Dei G, Bizzotto R, Mani A, Alain B. Incretin and Inflammatory Responses to Meals of Increasing Size in Healthy Subjects. J Clin Endocrinol Metab (2015) 100(2):561–8. doi: 10.1210/jc.2014-2865

23. Herrmann C, Goke R, Richter G, Fehm-Ha HC, Arnold R, Goke B, et al. Glucagon-Like Peptide-1 and Glucose-Dependent Insulin-Releasing Polypeptide Plasma Levels in Response to Nutrients. Digestion (1995) 56(2):117–26. doi: 10.1159/000201231

24. Færch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, et al. Greater Glucagon-Like Peptide-1 Responses to Oral Glucose are Associated With Glucagon-Like Peptide-1 Receptor Agonists, and SGLT2 Inhibitors. J Clin Endocrinol Metab (2018) 103(9):3513–23. doi: 10.1210/jc.2018-3507

25. Herrmann C, Goke R, Richter G, Fehm-Ha HC, Arnold R, Goke B, et al. Greater Glucagon-Like Peptide-1 Responses to Oral Glucose are Associated With Lower Central and Peripheral Blood Pressures. Cardiovasc Diabetol (2019) 18(1):130. doi: 10.1186/s12933-019-0497-7

26. Angagawa T. Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors. J Clin Med Res (2018) 10(10):796–7. doi: 10.14740/jcmsr3578w

27. Nauck MA, Meier JJ. MANAGEMENT OF ENDOCRINE DISEASE: Are All GLP-1 Agonists Equal in the Treatment of Type 2 Diabetes? Eur J Endocrinol (2018) 181(6):R211–34. doi: 10.1530/EJE-19-0566
38. Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S. Glucagon-Like Peptide-1, Glucose Homeostasis and Diabetes. *Trends Mol Med* (2008) 14(4):161–8. doi: 10.1016/j.molmed.2008.01.003

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Pan, Yuan and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.